When an innovative therapy aiming for a "one-time cure" is still evaluated by traditional standards that measure "months of survival," its failure may have been predetermined. In 2...
Exciting news for global biopharma companies! China's NMPA is proposing to slash clinical trial review times from 60 to just 30 working days for novel medicines – a game-changing development that...
